January 31, 2017 6:13pm
How much of sentiment is based on expectation … because what goes up like a rocket, invariably burns out like a shooting star
Which version of this reality is out there?
Pre-open indication’s tally: 0 hit and 5 miss (AGTC, BSTG, BLUE, CLBS and OSIR)
I answer one question; in which company should investors put, keep and commit their money!
… As I focus on the facts in evidence …
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.
U.S. equities closed mostly lower on Tuesday, but recorded monthly gains, as investors continued to evaluate the latest policies from the White House, while a slew of companies posted quarterly results.
The NASDAQ closed UP +1.07 or -0.02% to 5614.79 and the DOW closed DOWN -107.04 or -0.54% to 19,864.09.
A day in the life of the stem, cell, gene and regenerative therapy (SCGT & RT) sector – the advance/decline line scenario of our 43 covered companies:
- The open was positive with an A/DL of 28/13 and 2 flats;
- The mid-day stayed positive with an A/DL of 28/13 and 2 flats;
- The close continued positive with an A/DL of 32/11 and 1 flat;
Henry’omics:
From the mid-day’s investor’s letter, “Fact and fiction tend to merge over time; investors need to understand the difference.”
- As I had stated, “My admonition is … “Be on the right side of the facts … if material “things” are even disclosed”
In relation to the title … Why do managements claim one thing to be true while so many analysts assert another version of reality?
- I believe many measures, actions, material events and news “things” are subject to interpretation and translation which explain a lot about investor’s need to hear or ride opposing and affirming views.
I have worked on all sides of this industry, corporate, research, investing, the VC, buy and sell sides as well as in federal law enforcement following life as a military officer and I still question the basis and foundation of decision makers.
- I reject the prism of how corporate releases are based, created, organized and then legalized about what happened.
My question is … why this or that occurred.
- There is NO atlas or chart to making decisions.
This is just an example of what needs to be quantified – truth, not a version or iteration or even a “stretching” of the fine print!
- My “Bottom Line” is that there is an absence of evidence in many actions, if we are presented repeatedly with information as if it were … true, then we are inclined to engage into that set of “things” <as previously mentioned> that we are “programmed” to be believed true.
Seems a bit like conditioning investors <to me>or is it an effect of a “Stockholm Syndrome”!
- “Stockholm syndrome is a psychological condition that causes hostages to develop sympathetic sentiments towards their captors, often sharing their opinions and sympathies for “managements” as a survival strategy during their “portfolios captivity”.
These feelings, resulting from a bond formed between managements and investors during course of ownership are generally considered silly and in most cases unfounded in light of the risk endured by” by victims i.e. investors!
- But the fact is, we don’t have the time to research the legitimacy of what we read and hear.
I have and take the time …
Indexes, the ebb and flow:
- The iShares Russell 2000 (IWM) indicated a negative -0.28% in the pre- open and closed UP +0.70%.
- The iShares NASDAQ Biotechnology (IBB) did NOT indicate in the pre-open and closed UP +2.84%
Pre-open indication’s tally: 0 hit and 5 miss (AGTC, BSTG, BLUE, CLBS and OSIR)
- Applied Genetic Technologies (AGTC) closed DOWN -$0.15 – miss;
- Biostage (BSTG) closed UP +$0.012 – miss;
- bluebird bio (BLUE) closed UP +$5.90 – miss;
- Caladrius Biosciences (CLBS) closed UP +$0.36 – miss;
- Osiris (OSIR) closed UP +$0.03 – miss;
Today’s 5 top dollar gainers included:
- bluebird bio (BLUE) +$5.90 after Monday’s -$2.50 after Friday’s +$2.65 after Thursday’s +$0.65;
- Spark Therapeutics (ONCE) +$4.59 after Monday’s-$0.99 after Friday’s +$1.47 after Thursday’s -$0.53 after last Wednesday’s +$0.76;
- Kite Pharma (KITE) +$2.23 after Monday’s +$0.30 after Friday’s -$0.32;
- Juno Therapeutics (JUNO) +1.54;
- Bellicum Pharma (BLCM) +1.52;
Today’s 5 largest dollar losers of the session were:
- Applied Genetic Technologies (AGTC) -$0.15 after Monday’s -$0.75 after Friday’s FLAT at $8.15;
- VistaGen (VTGN) -$0.13;
- Mesoblast (MESO) -0.08;
- Athersys (ATHX) -$0.05;
- Fate therapeutics (FATE) -$0.05
Flat:
- Microbot (MBOT formerly STEM) at $1.28;
The downside trend reflects a pricing trend range of:
- Tuesday’s decliners ranged from -0.32% <NWBO> to -4.39% <ATHX> in 11 equities;
- Monday’s decliners ranged from -0.34% <KOOL> to -9.20% <AGTC> in 28 equities;
- Friday’s decliners ranged from -0.32% <VTGN> to -26.32% <ATHX> in 18 equities;
- Thursday’s decliners ranged from -0.02% <KITE> to -6.45% <AST> in 24 equities;
- Wednesday’s decliners ranged from -0.30% <BTX> to -7.444% <IMUC> in 12 equities;
- Last Tuesday’s decliners ranged from -0.44% <CAPR> to -3.57% <AGTC> in 15 equities;
The upside shows a pricing trend range of:
- Tuesday’s gainers ranged from +0.18% <QURE> to +12.81% <BLCM> in 32 equities;
- Monday’s gainers ranged from +0.00% <VTGN> to +3.29% <HSGX> in 9 equities;
- Friday’s gainers ranged from +0.25% <RGNX> to +12.77% <CLBS> in 23 equities;
- Thursday’s gainers ranged from +0.17% <MESO> to +4.95% <NWBO> in 14 equities;
- Wednesday’s gainers ranged from +0.22% <ONCE> to +10.49% <FCSC> in 28 equities;
- Last Tuesday’s gainers ranged from +0.35% <KOOL> to +14.78% <IMUC> in 26 equities;
The week’s beginning:
- Tuesday’s 32 gainers followed Monday’s 28, Friday’s 23, Thursday’s 14, Wednesday’s 28, Tuesday’s 26 and last Monday’s 13
- Tuesday’s 11 decliners followed Monday’s 28, Friday’s 18, Thursday’s 24, Wednesday’s 12, Tuesday’s 15 and last Monday’s 25
Review my fear gauge or the CBOE Volatility Index (VIX):
· Tuesday traded near 12;
· Monday traded near 12.3 – +16.5% higher;
· Friday traded near 10.5;
· Thursday traded near 10.9;
· Wednesday traded near 10.8;
· Last Tuesday traded near 11.4;
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
